drug_type
RELEVANT_DRUG
intervention_type
peptide immunotherapy/therapeutic vaccine
drug_description
A lyophilized peptide derived from human telomerase reverse transcriptase (hTERT) used as a therapeutic peptide vaccine; processed by antigen-presenting cells and presented via MHC to activate hTERT‑specific CD4+/CD8+ T‑cell responses, enabling immune recognition of telomerase‑expressing cells; administered subcutaneously.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
GV1001 peptide
drug_category
PEPTIDE VACCINE
drug_class
Vaccine
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
A synthetic peptide derived from human telomerase reverse transcriptase (hTERT) that is taken up by antigen-presenting cells and presented on MHC class I and II to activate hTERT-specific CD8+ and CD4+ T cells, enabling immune recognition and killing of telomerase-expressing cells.
drug_name
GV1001 (tertumotide)
nct_id_drug_ref
NCT06625710